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Immune Cell Profiling of IFN-l Response Shows pDCs
Express Highest Level of IFN-lR1 and Are Directly
Responsive via the JAK-STAT Pathway
Aoife Kelly,1,* Mark W. Robinson,1 Gerard Roche,1 Christine A. Biron,2
Cliona O’Farrelly,1,3,{ and Elizabeth J. Ryan4,5,{
The interferon lambda (IFN-l) cytokines have well-known antiviral properties, yet their contribution to immune
regulation is not well understood. Epithelial cells represent the major target cell of IFN-l; peripheral blood
mononuclear cells are generally considered nonresponsive, with the exception of plasmacytoid dendritic cells
(pDCs). In this study we aimed to define the potential for discrete subpopulations of cells to directly respond to
IFN-l. Analysis of peripheral blood leukocytes reveals that, while pDCs uniformly express the highest levels of
IFN-l receptor, a small proportion of B cells and monocytes also express the receptor. Nevertheless, B cells and
monocytes respond poorly to IFN-l stimulation in vitro, with minimal STAT phosphorylation and interferon-
stimulated gene (ISG) induction observed. We confirm that pDCs respond to IFN-l in vitro, upregulating their
expression of pSTAT1, pSTAT3, and pSTAT5. However, we found that pDCs do not upregulate pSTAT6 in
response to IFN-l treatment. Our results highlight unique aspects of the response to IFN-l and confirm that
while the IFN-l receptor is expressed by a small proportion of several different circulating immune cell
lineages, under normal conditions only pDCs respond to IFN-l stimulation with robust STAT phosphorylation
and ISG induction. The difference in STAT6 responsiveness of pDCs to type I and type III interferons may help
explain the divergence in their biological activities.
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Introduction
Interferons (IFNs) are widely known for their anti-viral properties and also have immune-regulatory func-
tions (Maher and others 2007). The diverse roles of Type I
and Type II IFNs in the immune system are well established,
but the immunological activity of the most recently dis-
covered Type III IFNs is unclear.
Type III IFNs (IFN-l) are related to both the Type I IFNs
and the IL-10 cytokine superfamily, but show less than 20%
amino acid identity with either family (Kotenko and others
2003; Sheppard and others 2003). IFN-l binds to the IFN-l
receptor, which is comprised of the shared IL-10R2 (IL-
10Rb) chain, and the IFN-l-specific IFN-lR1 chain, ex-
pressed predominantly on epithelial cell types (Sommereyns
and others 2008). In epithelial cells, IFN-l exerts similar
antiviral effects to the Type I IFNs, signaling through the
JAK-STAT pathway to induce IFN-stimulated genes (ISGs)
and upregulate MHC expression, although with differing
kinetics ( Jilg and others 2014). IFN-l can inhibit the repli-
cation of viruses including hepatitis C virus (HCV) (Robek
and others 2005; Zhu and others 2005; Marcello and others
2006; Zhang and others 2011), rotavirus (Pott and others
2011), influenza and respiratory syncytial virus (RSV)
(Mordstein and others 2008) within epithelial cells suggest-
ing a high level of redundancy between Type I and III IFNs.
This apparent redundancy is challenged by genetic studies
linking polymorphisms in the IFNL genomic region to dis-
eases including HCV infection (Ge and others 2009; Sup-
piah and others 2009; Tanaka and others 2009; Thomas and
others 2009) and asthma (Gaudieri and others 2012), and by
in vivo mouse studies that have demonstrated a protective
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effect of IFN-l on allergic airway disease (Koltsida and
others 2011). These findings imply that the Type III IFNs
have immune regulatory functions beyond the induction of
an antiviral cellular state, which may influence disease
susceptibility. However, evidence for a direct effect of IFN-
l on immune cells is limited and reports describing IFN-
lR1 expression on immune cells have been conflicting, with
data largely based on gene expression studies (Witte and
others 2009; Gallagher and others 2010). Published studies
have reported that peripheral blood mononuclear cells
(PBMCs) do not respond to IFN-l (Witte and others 2009;
Dickensheets and others 2013), with the exception of plas-
macytoid dendritic cells (pDCs) that express the receptor
and also respond to IFN-l treatment (Ank and others 2008;
Megjugorac and others 2009; Yin and others 2012). Some
studies on isolated immune populations have shown T reg-
ulatory cell induction by IFN-l-treated monocyte-derived
dendritic cells (Mennechet and Uze 2006), modulation of
the IFN-g response in monocyte-derived macrophages (Liu
and others 2011), and skewing of the Th1/Th2 response by
IFN-l ( Jordan and others 2007b). However, with many of
these studies, it is unclear whether the effect of IFN-l is
direct or indirect.
Here, we report a detailed investigation of how minimally
manipulated peripheral blood immune cell populations re-
spond to IFN-l stimulation. Using both flow cytometry and
real-time polymerase chain reaction measurement of receptor
expression and whole blood intracellular phosphorylated
STAT protein staining, our results provide a comprehensive
analysis of IFN-l receptor expression and the direct respon-
siveness of immune cells to IFN-l.
Materials and Methods
Cell isolation and purification
PBMCs were isolated from buffy coats sourced from the
Irish Blood Transfusion Service, from leukocyte cones
(National Blood Transfusion Service, Manchester, United
Kingdom) or from healthy donors recruited locally with
approval by Trinity College Ethics Committee. The PBMC
fraction was isolated by density centrifugation using Ficoll-
Paque Plus separation medium (GE Healthcare). T cells,
B cells, and monocytes were isolated using CD3, CD19, and
CD14 microbeads respectively or were sorted using the
Influx II (BD Bioscience), while pDCs were isolated using
the Diamond Plasmacytoid Dendritic Cell Isolation Kit II
(all from Miltenyi Biotec), as per manufacturer’s instruc-
tions. Cell purities were consistently >95%.
Stimulation of PBMCs with IFN-k and IFN-a
PBMCs or purified immune cell populations were cul-
tured at a density of 1 · 106/mL in Roswell Park Memorial
Institute medium (RPMI) supplemented with 10% fetal
bovine serum, 250 U/mL penicillin, and 250mg/mL strep-
tomycin (Gibco, Life Technologies) at 37C in 5% CO2.
Isolated pDCs were supplemented with recombinant human
IL-3 (1 ng/mL; Immunotools) to maintain viability. Cells
were stimulated with 100 ng/mL of IFN-l1 (IL-29), IFN-l2
(IL-28A) (both Peprotech) or IFN-l3 (IL-28B) (R&D Sys-
tems) or 1,000 U/mL IFN-a (Peprotech).
Characterization of IFN-k receptor
by flow cytometry
IFN-lR1 expression on peripheral blood leukocytes was
examined by flow cytometry. Briefly, 1 · 106 PBMCs were
stained for surface markers for 20 min in the dark at 4C
using the following antibodies: IFN-lR1 (IL-28Ra) (clone
MHLICR2a; Biolegend), IL-10R2 (clone 90220; R&D
Systems), CD3 (clone UCHT1; Biolegend), CD19 (clone
HIB19; Biolegend), CD56 (clone MEM-188; Biolegend),
HLA-DR (clone L234; Biolegend), CD14 (clone M5E2;
Biolegend), and CD16 (clone 3G8; Biolegend). Isotype
controls, IgG1 and IgG2a (both BD Bioscience), and fluo-
rescence minus one (FMO) controls were used to set pop-
ulation gates. For whole blood staining (DCs) 200mL of
fresh blood was stained with Lin1 (CD3, clone SK7; CD16,
clone 3G8; CD19, clone SJ25C1; CD20, clone L27; CD14,
clone MjP9; CD56, clone NCAM16.2; BD Bioscience),
HLA-DR (clone G46-6; BD Bioscience), CD11c (clone 3.9;
eBioscience), and CD123 (clone 6h6; eBioscience) for
20 min at RT followed by lysis of red blood cells using
FACS Lysing solution (BD Bioscience) for 10 min at RT.
Samples were washed and fixed in 1% paraformaldehyde
(Sigma-Aldrich) before analysis using the Canto II or LSR
Fortessa instrument (BD Bioscience) and FlowJo software
(Treestar, Inc.).
Whole blood staining to detect
STAT phosphorylation
Intracellular staining of whole blood was carried out to
detect upregulation of phosphorylated (p)STAT in response
to IFN-l treatment. Whole blood (200 mL) was either un-
treated or treated with IFN-l1, -l2 or l3 (100 ng/mL), or
IFN-a (1,000 U/mL) and incubated at 37C for the indicated
time points (15–90 min). After the stimulation period, the
Table 1. List of Primer Sequences Used for Real-Time Polymerase Chain Reaction
Target Primer sequence (5¢ to 3¢)
GAPDH [glyceraldehyde-3-phosphate dehydrogenase] F – AAAATCAAGTGGGGCGATGC
R – GAGGGGGCAGAGATGATGAC
RPS15 [ribosomal protein S15] F – CGGACCAAAGCGATCTCTTC
R – CGCACTGTACAGCTGCATCA
CXCL10 [chemokine (C-X-C motif) ligand 10] F – CCTGCAAGCCAATTTTGTCCA
R – TGTGGTCCATCCTTGGAAGC
ISG15 [ISG15 ubiquitin-like modifier] F – TTTGCCAGTACAGGAGCTTGTG
R - GGGTGATCTGCGCCTTCA
PKR [EIF2AK2; eukaryotic translation initiation factor 2-alpha kinase 2] F – TCTCAGCAGATACATCAGAGA
R–AGTATACTTTGTTTCTTTCATG
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cells were fixed immediately by adding Lyse/Fix Buffer (BD
Bioscience), followed by surface staining using the following
antibodies: CD45-AmCyan (clone 2D1; BD Bioscience),
CD3-pacific blue (clone UCHT1, BD Bioscience), CD303
(BDCA-2)-PE or APC (clone AC144; Miltenyi Biotec),
CD14-FITC (clone M5E2), Lin-1-FITC, CD19-FITC (clone
HIB19) (all BD Bioscience). Samples were incubated at RT
for 60 min followed by permeabilization for 30 min on ice
using Perm Buffer III (BD Bioscience) and intracellular
staining was carried out using BD Bioscience Phosflow an-
tibodies: STAT1-PE or Alexa 647 (clone 4a; pY701), STAT3-
PE or PE-CF594 (clone 4/P-STAT3; pY705), STAT4 PE or
PerCP-Cy5.5 (clone 38/pStat4; pY693), STAT5-Alexa 647 or
PE-Cy7 (clone 47/Stat5; pY694), STAT6-PE or V450 (clone
18/P-Stat6; pY641). Samples were incubated at RT for
60 min, then washed and acquired immediately using a Canto
II or LSR Fortessa flow cytometer (BD Bioscience). Data
were analyzed using FlowJo software.
FIG. 1. Expression of the IFN-l receptor chains IFN-lR1
and IL-10R2 on peripheral blood lymphocyte populations.
Expression of the IFN-lR1 and IL-10R2 receptor chains
were measured by flow cytometry on CD3+, CD19+, and
CD56+ cells in healthy donor PBMCs, gating on lympho-
cytes by FSC SSC (n = 5). Graphs show the percentage
positive of IFN-lR1 and IL-10R2 expression from n = 5
healthy donors. Gates were set based on isotype and FMO
controls. Error bars show SEM. FMO, fluorescence minus
one; PBMC, peripheral blood mononuclear cells.
FIG. 2. Expression of the IFN-l receptor chains IFN-lR1
and IL-10R2 on peripheral blood monocyte populations.
Expression of the IFN-lR1 and IL-10R2 receptor chains
were measured by flow cytometry on healthy donor PBMC
monocyte populations. Following gating on the monocyte
gate by FSC SSC and HLA-DR+ cells, the populations were
gated to distinguish CD14+ classical monocytes, CD14+
CD16+ intermediate monocytes, and CD16+ nonclassical
monocytes and the % positive IFN-lR1 and IL-10R2 re-
ceptor cells shown (n = 5). Error bars show SEM.
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Real-time PCR: ISGs and IFNLR1
RNA was extracted from isolated pDCs and B cells (1–
5 · 105 cells) using either RNeasy micro or mini kits (Qia-
gen), according to the manufacturer’s instructions. The
TRIzol (Life Technologies, Invitrogen) method was used to
extract RNA from monocytes, and T cells (1–2 · 106 cells).
Synthesis of cDNA was performed using the Omniscript
reverse transcription kit (Qiagen). Quantitative PCR was
carried out using the SensiMix SYBRgreen (BioLine) on
a Mx3000P instrument (Stratagene). Each reaction was
carried out in duplicate in a total volume of 20mL. Primers
were designed to be intron-spanning using Primer3 or Primer
Express v3.0 software (Applied Biosystems). To measure
the cellular transcriptional response to IFN stimulation, 3 ISG
targets, CXCL10, ISG15, and PKR, were selected based on
published results investigating the transcriptional response in
IFN-stimulated PBMCs (Waddell and others 2010). The
following cycling parameters were used: 95C for 30 s, 60C
for 1 min and 72C for 30 s, followed by amplicon dissocia-
tion. For gene induction assays, fold change values were
calculated using the DDCt method. The geometric mean of
the Ct values of 2 reference genes, GAPDH and RPS15, was
used as a reference value and each sample was individually
calibrated using the Ct value of the untreated sample. Primer
sequences are listed in Table 1. For measurement of IFNLR1,
RNA was extracted from cell populations using the RNeasy
mini or micro kits and reverse transcribed using superscript
III reverse transcriptase (Life Technologies) and IFNLR1
expression was measured by real-time PCR using TaqMan
gene expressions assay (Hs00417120_m1; Life Technolo-
gies) using the Quantstudio 12K Flex instrument (Life
Technologies). Input cDNA was 10 ng/reaction in 20 mL re-
action using TaqMan Universal mastermix II with UNG
(Life Technologies) and gene expression was normalized
to the housekeeping gene beta 2 microglobulin (B2M)
(Hs00984230_m1; Life Technologies) and expressed as a
ratio of the Ct of gene of interest to housekeeping gene. Re-
sults are expressed as mean – SEM. Statistical analysis was
carried out using one-way ANOVA, with Tukey’s post-test.
P < 0.05 was considered statistically significant; *P < 0.05,
**P < 0.01, ***P < 0.005, ****P < 0.001.
Results
The IFN-k receptor is expressed on B cells,
monocytes, and DCs
To define the extent of IFN-l receptor expression by cir-
culating immune cells, PBMCs were stained with antibodies
FIG. 3. Expression of IFN-l re-
ceptor on pDCs. (A) IFN-lR1 and
IL-10R2 expression was measured
on CD123+ plasmacytoid and
CD11c+ myeloid dendritic cells
from the fresh whole blood of
healthy donors. (i) Following gating
on single cells by light scattering,
dendritic cells were identified by
first gating on Lin1- HLA-DR+
population, followed by CD11c and
CD123. Gates were set based on
FMO controls and isotype controls
(shown) (ii) The MFI of IFN-lR1
and IL-10R2 expression from n = 3
healthy donors is presented follow-
ing subtraction of the isotype con-
trol for each cell type. Error bars
show SEM. (B) RNA was extracted
from total PBMCs or isolated CD3+
T cells, CD19+ B cells, CD14+
monocytes, or BDCA-4+ pDCs and
IFNLR1 expression was measured by
real-time PCR. Results are expressed
as mean – SEM. Statistical analysis
was carried out using one-way
ANOVA, with Tukey’s post-test;
****P < 0.001. pDC, plasmacytoid
dendritic cell.
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specific for IFN-lR1 and IL-10R2 and expression measured
by flow cytometry, gating on CD3+ T cells, CD19+ B cells,
CD56+ NK cells, and different populations of monocytes:
CD14+ classical, CD14+CD16+ intermediate, and CD16+
nonclassical monocytes. Within the lymphocyte gate, IFN-
lR1 expression was only detectable on a small proportion of
CD19+ B cells, and was absent from T cells and NK cells
(n = 5) (Fig. 1). We found that a low percentage of monocytes
expressed IFN-lR1 (Fig. 2). Both CD19+ B cells and all of
the monocyte subsets examined expressed the IL-10R2 re-
ceptor chain (Figs. 1 and 2), suggesting that these cell types
may be capable of responding to IFN-l under appropriate
conditions.
Next, the expression IFN-lR1 and IL-10R2 by DC sub-
sets was investigated. DCs were identified by gating on
Lin1- HLA-DR+ cells within which myeloid DCs can be
FIG. 4. IFN-l induces STAT phosphorylation in pDCs from peripheral blood. (A) Whole blood (200mL) was treated with
1,000 U/mL IFN-a or 100 ng/mL IFN-l1 for 30 min. Red cells were then lysed, fixed and stained with the pan-leukocyte
marker CD45. Following permeabilization, intracellular staining was performed using antibodies against pSTAT1 and
pSTAT3 and cells were acquired immediately on a flow cytometer. (B) STAT phosphorylation was examined in the
lymphocyte gate, monocyte/DC gate, and gating on Lin1- BDCA-2+ pDCs. (C) Phosphorylation of STAT1 was measured
by flow cytometry in pDCs in response to 10 ng/mL and 100 ng/mL IFN-l1 and 1,000 U/mL IFN-a. Flow plots are
representative of at least n = 3 healthy donors.
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identified by the expression of CD11c. The marker CD123
(IL-3 receptor) is used to identify pDCs (Fig. 3A i), which
are also commonly identified by expression of the pDC-
specific marker BDCA-2. The BDCA-4 marker is used
for pDC isolation as isolation based on BDCA-2 triggers
changes in cell function and is thus avoided. Relative to the
isotype control, pDCs and mDCs expressed the IFN-lR1
and IL-10R2 chains of the IFN-l receptor (Fig. 3A i, ii). To
confirm flow cytometry data, IFNLR1 was also measured on
pDCs and FACS-sorted CD3+ T cells, CD19+ B cells, and
CD14+ monocytes by real-time PCR. pDCs expressed con-
siderably higher levels of IFNLR1 compared to all other
immune cell populations tested (Fig. 3B). IFNLR1 expres-
sion was also detectable on B cells, T cells, and monocytes
although at markedly reduced levels.
IFN-k induces robust STAT phosphorylation
in pDCs
As DCs and a small proportion of B cells and monocytes
express the IFN-l receptor, we measured the response of
these cells to IFN-l treatment. Activation of the JAK-STAT
pathway (as evidenced by pSTAT1 and pSTAT3) by IFN-l
was measured in total PBMCs treated with 100 ng/mL IFN-
l1 for 30 min, with IFN-a treatment (1,000 U/mL) for
30 min included as a positive control. No STAT phosphor-
ylation was detectable in total PBMCs (CD45+) treated with
IFN-l, while robust induction of pSTAT1 and pSTAT3 was
observed in response to IFN-a (Fig. 4A). Increasing IFN-l1
concentration up to 500 ng/mL and treatment from 15 to
90 min failed to induce discernible STAT1 or STAT3 phos-
phorylation upon analysis of total PBMCs (data not shown).
STAT phosphorylation in response to IFN-l1 was absent
when immune cells were separated into lymphocytes and
monocytes on the basis of forward and side scatter (Fig. 4B).
However, within the Lin1- BDCA-2+ pDC gate, pSTAT1
upregulation in response to IFN-l1 (100 ng/mL) was clearly
observed at 30 min (Fig. 4B). Dose response experiments
demonstrated that as little as 10 ng/mL of IFN-l1 induced
pSTAT1 in pDCs, with increased levels observed with
100 ng/mL (Fig. 4C). Specific staining of CD3+ T cells,
CD19+ B cells, and CD14+ monocytes failed to show any
STAT phosphorylation in response to IFN-l at time points up
to 90 min (data not shown).
FIG. 5. IFN-l induces phosphorylation of STAT1, 3, and 5, but not STAT6, in pDCs. (A) Whole blood (200mL) from
healthy donors (n = 3) was treated with 100 ng/mL IFN-l1, IFN-l2, and IFN-l3 or 1,000 U/mL IFN-a for 30 min. Following
red blood cell lysis, cells were fixed and stained with lin1 and the pDC-specific surface marker BDCA-2. The cells were
permeabilized and intracellular staining was carried out using antibodies against phospho-STAT1, STAT3, STAT4, STAT5,
and STAT6. (B) The mean percentage STAT phosphorylation is shown for pDCs treated with either (i) IFN-l1 or (ii) IFN-a
at time points of 15–90 min as indicated, with the unstimulated sample gated at less than 3%. Error bars indicate SEM.
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pDCs show a unique profile of STAT
phosphorylation in response to IFN-k
To provide a complete picture of STAT signaling fol-
lowing IFN-l stimulation in pDCs, phosphorylation of
STAT1, 3, 4, 5, and 6 were measured. IFN-l1, IFN-l2, and
IFN-l3 acted in a similar manner, inducing pSTAT1,
pSTAT3, and pSTAT5 upregulation in pDCs after 30 min
treatment of whole blood (Fig. 5A). Measurement of the
IFN-l1-induced pSTAT response over a time course of
0–90 min revealed that the pattern of IFN-l1-induced STAT
phosphorylation in pDCs mirrored that seen with IFN-a
treatment of pDCs, although at lower levels (Fig. 5A, B).
Both IFN-l1 and IFN-a induced phosphorylation of STATs
1, 3, and 5; however, unlike IFN-a, IFN-l1 failed to induce
phosphorylation of STAT6. IFN-a and IFN-l1 both failed to
induce phosphorylation of STAT4 in pDCs (Fig. 5A, B).
IFN-k treatment induces minimal ISG expression
in immune cell populations
Next, we sought to identify whether the ability of IFN-l
to induce ISGs was limited to those cells that expressed the
IFN-lR1 and demonstrated increased STAT phosphoryla-
tion, namely pDCs. Expression of well-characterized ISGs
CXCL10, ISG15, and PKR were measured in purified pDCs,
B cells, T cells, and monocytes treated with IFN-l1. ISG
expression was measured following IFN-a stimulation as
a positive control (except for pDCs due to limited cell
numbers). All cell types responded to IFN-a stimulation
upregulating CXCL10, ISG15, and PKR expression indi-
cating they were viable and capable of responding to stimuli
(Fig. 6).
The highest IFN-l1-induced gene expression was evi-
dent in pDCs (25.6-, 14.7-, and 3.6-fold change for
CXCL10, ISG15 and PKR respectively). However, some
ISG induction was also present in B cells, and monocytes
(Fig. 6). The ISG responses observed in B cells and
monocytes were minimal, representing only a fraction of
the response to IFN-a stimulation. Among these 3 immune
cell types, B cells had the most consistent ISG induction
with 6.3-, 7.5- and 14.4-fold induction of CXCL10, ISG15,
and PKR respectively, while monocytes only showed in-
creased CXCL10 expression.
Discussion
Here, we hypothesized that IFN-ls might play a key role in
the regulation of immune response and exerting antiviral
activity in epithelial cells. We therefore sought to systemat-
ically profile the expression of IFN-lR1 by human peripheral
blood leukocyte populations and their responsiveness to the
direct effects of IFN-l1. We found that while pDCs express
the highest level of the specific IFN-lR1 chain, a small pro-
portion of B cells and monocytes in peripheral blood also
express IFN-lR1. Despite receptor expression, robust STAT
phosphorylation in response to IFN-l was only observed in
pDCs. Similarly, ISG induction in response to IFN-l was
significantly higher in pDCs compared to B cells or mono-
cytes. Our data confirm that pDCs are the predominant IFN-
l-responsive cell type within peripheral blood under normal
conditions.
Several previous studies have demonstrated that epithe-
lial cells, including hepatocytes, express the IFN-l recep-
tor and are responsive to IFN-l (Sommereyns and others
2008; Dickensheets and others 2013), while PBMCs (lym-
phocytes and monocytes) fail to respond directly to IFN-l
(Witte and others 2009; Dickensheets and others 2013).
These studies defined receptor expression using PCR-based
techniques rather than direct detection of receptor expres-
sion on cell surfaces. Also, most studies used Western blot
to visualize STAT proteins, which lacks the sensitivity to
accurately measure STAT phosphorylation in rare immune
cell populations. To overcome these technical limitations,
we adopted sensitive flow cytometry-based approaches for
the analysis of IFN-l receptor expression and STAT protein
phosphorylation (Miyagi and others 2010). This approach
has been used previously by Witte and others to study IFN-
l response in lymphocytes and monocytes (Witte and oth-
ers 2009) but we extended our study to include additional
rare cell types such as DCs. We developed a staining
FIG. 6. IFN-l induces expression of the antiviral genes
CXCL10, ISG15, and PKR in peripheral blood immune
populations. BDCA-4+ pDCs, CD19+ B cells, CD14+
monocytes, and CD3+ T cells were isolated from peripheral
blood mononuclear cells (PBMCs) by magnetic bead sepa-
ration and cultured either untreated or treated with (A) IFN-
l1 (100 ng/mL) or (B) IFN-a (1,000 U/mL) for 4 h. Following
RNA extraction, CXCL10, ISG15, and PKR expression was
measured using real-time PCR. Fold change is shown relative
to the untreated sample for each cell type (as indicated by
dotted line) and values were normalized to the mean of 2
housekeeping genes GAPDH and RPS15 using the DDCt
method. Each bar represents the mean of n = 5–6 blood donors
for B cells, T cells, and monocytes and n = 3 donors for pDCs.
Error bars show SEM.
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strategy using antibody combinations that allowed us to
detect pSTAT 1, 3, 4, 5, and 6 in CD45+ total PBMCs,
CD3+ T cells, CD19+ B cells, CD14+ monocytes, and
CD303+ (BDCA-2) pDCs. In addition, we utilized a whole
blood staining protocol, performed using freshly drawn
blood, which preserves rare cell populations and minimizes
cell manipulation to reduce basal signal activation (Chow
and others 2005). This experimental strategy enabled
quantitative measurement of STAT phosphorylation within
a mixed population of cells and excluded potential induc-
tive effects of cell isolation.
We found that pDCs and a small proportion of B cells and
monocytes expressed IFN-l receptor on their cell surface,
providing the potential for these cells to respond to IFN-l.
IFN-l1 did not induce detectable STAT phosphorylation
when CD45+ PBMCs were examined as a whole, in stark
contrast to robust pSTAT1 and 3 induced by IFN-a. Of the
immune cell types assessed, only pDCs responded to IFN-
l1, with increased pSTAT1, pSTAT3, and pSTAT5 ob-
served. This is in agreement with a previous report showing
pSTAT1 in response to IFN-l in pDCs (Yin and others
2012). The pDC population represents less than 1% of total
leukocytes and therefore any STAT response in this small
population will be masked in whole PBMC preparations.
Despite the lack of STAT phosphorylation detected in B
cells and monocytes in response to IFN-l treatment, ISG
expression was increased in these cells. T cells did not up-
regulate ISG in response to IFN-l treatment, corresponding
with the fact that very few, if any, CD3+ T cells expressed
IFN-lR1. The minimal IFN-l response observed in B cells
and monocytes may play a role in priming these cell types
and indeed previous research has indicated that monocytes
become responsive to IFN-l during their development into
monocyte-derived macrophages (Liu and others 2011).
Monocytes have been reported to produce IL-6, IL-8, and
IL-10 in response to IFN-l ( Jordan and others 2007a). This
implies that monocytes are capable of responding to IFN-l
under certain conditions. Our observation of B-cell expres-
sion of the IFN-lR1 and ISG induction is supported by a
recent study, which found that the receptor is expressed on
both naı̈ve and memory B cells and that treatment with IFN-
l did induce ISGs OAS and Mx1. However, IFN-l-induced
B-cell activation and changes in antibody and cytokine
production only occurred in the presence of a TLR7 ligand
(de Groen and others 2015). This finding highlights the
importance of the environmental context and presence of co-
stimulatory signals in the function of IFN-l. Our results
indicate that IFN-l may also prime or have indirect effects
on both monocytes and B cells, in addition to the more
pronounced direct effects on pDCs.
IFN-l1 induces phosphorylation of STAT1, 3, and 5 in
pDCs in a dose and time-dependent manner. This pattern of
STAT phosphorylation in pDCs in response to IFN-l1
parallels that seen following IFN-a stimulation, with one
exception; IFN-a is capable of inducing phosphorylation of
STAT6 in pDCs, while IFN-l1 is not. The activation of
STAT6 by Type I IFNs has been described in B-cell lines
(Gupta and others 1999) and human T cells (Eriksen and
others 2004) but, to the best of our knowledge, has not been
previously reported in pDCs. STAT6 is likely to be of im-
portance in the innate immune response, as STAT6 knock-
out mice show higher susceptibility to infection (Chen and
others 2011). This unique pattern of STAT6 responsiveness
may explain the functional divergence in the response to
Type I and Type III IFNs, with further study required to
establish the biological relevance of this observation.
It has been established that a significant amount of IFN-l
is produced by human CD141+ DCs (Kelly and others 2014)
or murine CD8a+ DCs (Lauterbach and others 2010); it is
also produced by pDCs (Yin and others 2012; Zhang and
others 2013) although at lower levels than mDCs (Zhang
and others 2013). DCs serve as a key link between the innate
and adaptive immune response and IFN produced by DCs is
known to act in a paracrine and autocrine manner to pro-
mote differentiation and maturation of DCs (Montoya and
others 2002). Therefore, IFN-l produced by mDCs in re-
sponse to TLR ligation may serve to promote strong pSTAT
responses in neighboring pDCs, thus amplifying the re-
sponse. This is supported by previous studies suggesting that
IFN-l sustains IFN-a production by pDCs in viral infection
(Yin and others 2012; Zhang and others 2013).
Our evaluation of the peripheral blood leukocyte response
to IFN-l treatment clearly shows pDCs are the predominant
direct immunological target of IFN-l in the blood. How-
ever, IFN-l may also act on other immune cell types par-
ticularly B cells and monocytes given that a proportion of
these cells express the receptor. Studies of the immuno-
logical effects of IFN-l should not solely focus on pDC but
also consider the effects on B cells and monocytes under the
given conditions.
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